Listed

Alnylam Pharmaceuticals, Inc.

ALNYNasdaqCIK 1178670HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.46bn, Q3 FY2026
Operating income$345.8m, Q3 FY2026
Net income$2.17bn, Q3 FY2026
Alnylam Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31period not labelled2026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Revenue$m440Revenue, Q4 FY2023, three months to 2023-12-31$439.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure494Revenue, Q1 FY2024, three months to 2024-03-31$494.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure660Revenue, Q2 FY2024, three months to 2024-06-30$659.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure501Revenue, Q3 FY2024, three months to 2024-09-30$500.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure593Revenue, Q4 FY2024, three months to 2024-12-31$593.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure594Revenue, Q1 FY2025, three months to 2025-03-31$594.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure774Revenue, Q2 FY2025, three months to 2025-06-30$773.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure1,249Revenue, Q3 FY2025, three months to 2025-09-30$1.25bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure1,097Revenue, Q4 FY2025, three months to 2025-12-31$1.10bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figurenot reported1,291Revenue, Q2 FY2026, three months to 2026-06-30$1.29bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure1,458Revenue, Q3 FY2026, three months to 2026-09-30$1.46bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Cost of revenue$m72.0Cost of revenue, Q4 FY2023, three months to 2023-12-31$72.0m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure54.6Cost of revenue, Q1 FY2024, three months to 2024-03-31$54.6m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure67.3Cost of revenue, Q2 FY2024, three months to 2024-06-30$67.3m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure82.0Cost of revenue, Q3 FY2024, three months to 2024-09-30$82.0m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure103Cost of revenue, Q4 FY2024, three months to 2024-12-31$102.6m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure70.2Cost of revenue, Q1 FY2025, three months to 2025-03-31$70.2m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure142Cost of revenue, Q2 FY2025, three months to 2025-06-30$142.0m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure197Cost of revenue, Q3 FY2025, three months to 2025-09-30$197.2m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure268Cost of revenue, Q4 FY2025, three months to 2025-12-31$267.7m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figurenot reported298Cost of revenue, Q2 FY2026, three months to 2026-06-30$298.3m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure362Cost of revenue, Q3 FY2026, three months to 2026-09-30$361.8m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Research and development$m272Research and development, Q4 FY2023, three months to 2023-12-31$272.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure261Research and development, Q1 FY2024, three months to 2024-03-31$261.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure294Research and development, Q2 FY2024, three months to 2024-06-30$294.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure271Research and development, Q3 FY2024, three months to 2024-09-30$270.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure300Research and development, Q4 FY2024, three months to 2024-12-31$300.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure265Research and development, Q1 FY2025, three months to 2025-03-31$265.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure324Research and development, Q2 FY2025, three months to 2025-06-30$323.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure359Research and development, Q3 FY2025, three months to 2025-09-30$358.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure372Research and development, Q4 FY2025, three months to 2025-12-31$372.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figurenot reported413Research and development, Q2 FY2026, three months to 2026-06-30$413.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure409Research and development, Q3 FY2026, three months to 2026-09-30$408.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Selling, general and administrative$m198Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$198.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure211Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$210.8m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure248Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$248.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure221Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$221.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure295Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$295.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure240Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$239.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure323Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$323.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure322Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$322.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure325Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$325.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figurenot reported348Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$347.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure342Selling, general and administrative, Q3 FY2026, three months to 2026-09-30$342.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Operating income$m(116)Operating income, Q4 FY2023, three months to 2023-12-31−$116.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure(43.4)Operating income, Q1 FY2024, three months to 2024-03-31−$43.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure48.6Operating income, Q2 FY2024, three months to 2024-06-30$48.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure(76.9)Operating income, Q3 FY2024, three months to 2024-09-30−$76.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure(105)Operating income, Q4 FY2024, three months to 2024-12-31−$105.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure18.1Operating income, Q1 FY2025, three months to 2025-03-31$18.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure(16.2)Operating income, Q2 FY2025, three months to 2025-06-30−$16.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure368Operating income, Q3 FY2025, three months to 2025-09-30$368.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure132Operating income, Q4 FY2025, three months to 2025-12-31$131.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figurenot reported231Operating income, Q2 FY2026, three months to 2026-06-30$231.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure346Operating income, Q3 FY2026, three months to 2026-09-30$345.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Interest expense$m31.3Interest expense, Q4 FY2023, three months to 2023-12-31$31.3m. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-02-15, accession 0001178670-24-000008. Derived: 12-month figure less the 9-month figure.Report this figure35.3Interest expense, Q1 FY2024, three months to 2024-03-31$35.3m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-02, accession 0001178670-24-000023.Report this figure33.3Interest expense, Q2 FY2024, three months to 2024-06-30$33.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure34.4Interest expense, Q3 FY2024, three months to 2024-09-30$34.4m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure39.0Interest expense, Q4 FY2024, three months to 2024-12-31$39.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure58.3Interest expense, Q1 FY2025, three months to 2025-03-31$58.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-12, accession 0001628280-26-007497.Report this figure61.5Interest expense, Q2 FY2025, three months to 2025-06-30$61.5m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure67.5Interest expense, Q3 FY2025, three months to 2025-09-30$67.5m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure65.4Interest expense, Q4 FY2025, three months to 2025-12-31$65.4m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figurenot reported82.1Interest expense, Q2 FY2026, three months to 2026-06-30$82.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure84.4Interest expense, Q3 FY2026, three months to 2026-09-30$84.4m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Income tax$m0.2Income tax, Q4 FY2023, three months to 2023-12-31$183.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure2.3Income tax, Q1 FY2024, three months to 2024-03-31$2.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure5.7Income tax, Q2 FY2024, three months to 2024-06-30$5.7m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure2.9Income tax, Q3 FY2024, three months to 2024-09-30$2.9m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure(110)Income tax, Q4 FY2024, three months to 2024-12-31−$110.2m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure15.9Income tax, Q1 FY2025, three months to 2025-03-31$15.9m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure30.9Income tax, Q2 FY2025, three months to 2025-06-30$30.9m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure(12.1)Income tax, Q3 FY2025, three months to 2025-09-30−$12.1m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure(25.3)Income tax, Q4 FY2025, three months to 2025-12-31−$25.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figurenot reported13.3Income tax, Q2 FY2026, three months to 2026-06-30$13.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure(1,872)Income tax, Q3 FY2026, three months to 2026-09-30−$1.87bn. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Net income$m(138)Net income, Q4 FY2023, three months to 2023-12-31−$137.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure(65.9)Net income, Q1 FY2024, three months to 2024-03-31−$65.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure(16.9)Net income, Q2 FY2024, three months to 2024-06-30−$16.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure(112)Net income, Q3 FY2024, three months to 2024-09-30−$111.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure(83.8)Net income, Q4 FY2024, three months to 2024-12-31−$83.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure(18.3)Net income, Q1 FY2025, three months to 2025-03-31−$18.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure(72.2)Net income, Q2 FY2025, three months to 2025-06-30−$72.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure293Net income, Q3 FY2025, three months to 2025-09-30$292.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure112Net income, Q4 FY2025, three months to 2025-12-31$111.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure206Net income, period not labelled, three months to 2026-03-31$206.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure164Net income, Q2 FY2026, three months to 2026-06-30$164.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure2,167Net income, Q3 FY2026, three months to 2026-09-30$2.17bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Diluted EPS$ per sharenot reported(0.52)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure(0.13)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure(0.87)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figurenot reported(0.14)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-12, accession 0001628280-26-007497.Report this figure(0.55)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure2.14Diluted EPS, Q3 FY2025, three months to 2025-09-30$2.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figurenot reportednot reported1.21Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure15.72Diluted EPS, Q3 FY2026, three months to 2026-09-30$15.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Basic EPS$ per sharenot reported(0.52)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure(0.13)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure(0.87)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.87 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figurenot reported(0.14)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-K filed 2026-02-12, accession 0001628280-26-007497.Report this figure(0.55)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure2.23Basic EPS, Q3 FY2025, three months to 2025-09-30$2.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figurenot reportednot reported1.23Basic EPS, Q2 FY2026, three months to 2026-06-30$1.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure16.19Basic EPS, Q3 FY2026, three months to 2026-09-30$16.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure

Balance sheet

Cash and equivalents$1.75bn, Q3 FY2026
Shareholders' equity$3.60bn, Q3 FY2026
Alnylam Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitFY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31period not labelled2026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Cash and equivalents$m813Cash and equivalents, FY2023, at 2023-12-31$812.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-12, accession 0001628280-26-007497.Report this figure682Cash and equivalents, Q1 FY2024, at 2024-03-31$681.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure968Cash and equivalents, Q2 FY2024, at 2024-06-30$968.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure1,100Cash and equivalents, Q3 FY2024, at 2024-09-30$1.10bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure966Cash and equivalents, FY2024, at 2024-12-31$966.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-12, accession 0001628280-26-007497.Report this figure1,020Cash and equivalents, Q1 FY2025, at 2025-03-31$1.02bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure1,114Cash and equivalents, Q2 FY2025, at 2025-06-30$1.11bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure1,490Cash and equivalents, Q3 FY2025, at 2025-09-30$1.49bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure1,657Cash and equivalents, FY2025, at 2025-12-31$1.66bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figurenot reported1,708Cash and equivalents, Q2 FY2026, at 2026-06-30$1.71bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure1,754Cash and equivalents, Q3 FY2026, at 2026-09-30$1.75bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Current assets$m2,983Current assets, FY2023, at 2023-12-31$2.98bn. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-13, accession 0001178670-25-000026.Report this figure2,989Current assets, Q1 FY2024, at 2024-03-31$2.99bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-02, accession 0001178670-24-000023.Report this figure3,173Current assets, Q2 FY2024, at 2024-06-30$3.17bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-01, accession 0001178670-24-000041.Report this figure3,355Current assets, Q3 FY2024, at 2024-09-30$3.36bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-10-31, accession 0001178670-24-000053.Report this figure3,295Current assets, FY2024, at 2024-12-31$3.30bn. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-12, accession 0001628280-26-007497.Report this figure3,268Current assets, Q1 FY2025, at 2025-03-31$3.27bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure3,644Current assets, Q2 FY2025, at 2025-06-30$3.64bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure3,953Current assets, Q3 FY2025, at 2025-09-30$3.95bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure4,051Current assets, FY2025, at 2025-12-31$4.05bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figurenot reported4,620Current assets, Q2 FY2026, at 2026-06-30$4.62bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure5,113Current assets, Q3 FY2026, at 2026-09-30$5.11bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Total assets$m3,830Total assets, FY2023, at 2023-12-31$3.83bn. XBRL concept us-gaap:Assets. 10-K filed 2025-02-13, accession 0001178670-25-000026.Report this figure3,824Total assets, Q1 FY2024, at 2024-03-31$3.82bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-02, accession 0001178670-24-000023.Report this figure4,010Total assets, Q2 FY2024, at 2024-06-30$4.01bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-01, accession 0001178670-24-000041.Report this figure4,205Total assets, Q3 FY2024, at 2024-09-30$4.21bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-10-31, accession 0001178670-24-000053.Report this figure4,240Total assets, FY2024, at 2024-12-31$4.24bn. XBRL concept us-gaap:Assets. 10-K filed 2026-02-12, accession 0001628280-26-007497.Report this figure4,214Total assets, Q1 FY2025, at 2025-03-31$4.21bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure4,566Total assets, Q2 FY2025, at 2025-06-30$4.57bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure4,852Total assets, Q3 FY2025, at 2025-09-30$4.85bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure4,966Total assets, FY2025, at 2025-12-31$4.97bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figurenot reported5,559Total assets, Q2 FY2026, at 2026-06-30$5.56bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure7,995Total assets, Q3 FY2026, at 2026-09-30$7.99bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Current liabilities$m968Current liabilities, FY2023, at 2023-12-31$967.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-13, accession 0001178670-25-000026.Report this figure942Current liabilities, Q1 FY2024, at 2024-03-31$941.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-02, accession 0001178670-24-000023.Report this figure1,055Current liabilities, Q2 FY2024, at 2024-06-30$1.06bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-01, accession 0001178670-24-000041.Report this figure1,221Current liabilities, Q3 FY2024, at 2024-09-30$1.22bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-10-31, accession 0001178670-24-000053.Report this figure1,186Current liabilities, FY2024, at 2024-12-31$1.19bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-12, accession 0001628280-26-007497.Report this figure1,076Current liabilities, Q1 FY2025, at 2025-03-31$1.08bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure1,301Current liabilities, Q2 FY2025, at 2025-06-30$1.30bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure1,555Current liabilities, Q3 FY2025, at 2025-09-30$1.56bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure1,466Current liabilities, FY2025, at 2025-12-31$1.47bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figurenot reported1,513Current liabilities, Q2 FY2026, at 2026-06-30$1.51bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure2,063Current liabilities, Q3 FY2026, at 2026-09-30$2.06bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Total liabilities$m4,051Total liabilities, FY2023, at 2023-12-31$4.05bn. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-13, accession 0001178670-25-000026.Report this figure4,044Total liabilities, Q1 FY2024, at 2024-03-31$4.04bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-02, accession 0001178670-24-000023.Report this figure4,013Total liabilities, Q2 FY2024, at 2024-06-30$4.01bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-01, accession 0001178670-24-000041.Report this figure4,173Total liabilities, Q3 FY2024, at 2024-09-30$4.17bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-10-31, accession 0001178670-24-000053.Report this figure4,173Total liabilities, FY2024, at 2024-12-31$4.17bn. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-12, accession 0001628280-26-007497.Report this figure4,098Total liabilities, Q1 FY2025, at 2025-03-31$4.10bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure4,315Total liabilities, Q2 FY2025, at 2025-06-30$4.32bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure4,618Total liabilities, Q3 FY2025, at 2025-09-30$4.62bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure4,177Total liabilities, FY2025, at 2025-12-31$4.18bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figurenot reported4,205Total liabilities, Q2 FY2026, at 2026-06-30$4.20bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure4,391Total liabilities, Q3 FY2026, at 2026-09-30$4.39bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(221)Shareholders' equity, FY2023, at 2023-12-31−$220.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-12, accession 0001628280-26-007497.Report this figure(219)Shareholders' equity, Q1 FY2024, at 2024-03-31−$219.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure(3.1)Shareholders' equity, Q2 FY2024, at 2024-06-30−$3.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure32.4Shareholders' equity, Q3 FY2024, at 2024-09-30$32.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure67.1Shareholders' equity, FY2024, at 2024-12-31$67.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure426Shareholders' equity, Q1 FY2025, at 2025-03-31$426.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure555Shareholders' equity, Q2 FY2025, at 2025-06-30$555.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure580Shareholders' equity, Q3 FY2025, at 2025-09-30$580.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure789Shareholders' equity, FY2025, at 2025-12-31$789.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure1,075Shareholders' equity, period not labelled, at 2026-03-31$1.08bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure1,354Shareholders' equity, Q2 FY2026, at 2026-06-30$1.35bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure3,604Shareholders' equity, Q3 FY2026, at 2026-09-30$3.60bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure

Cash flow

Operating cash flow$341.0m, Q3 FY2026
Capital expenditure$69.8m, Q3 FY2026
Alnylam Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q3 FY20262026-09-30
Operating cash flow$m(59.0)Operating cash flow, Q2 FY2023, three months to 2023-06-30−$59.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-08-01, accession 0001178670-24-000041. Derived: 6-month figure less the 3-month figure.Report this figure359Operating cash flow, Q3 FY2023, three months to 2023-09-30$359.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-10-31, accession 0001178670-24-000053. Derived: 9-month figure less the 6-month figure.Report this figure(29.8)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$29.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure(81.5)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$81.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure124Operating cash flow, Q2 FY2024, three months to 2024-06-30$124.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-07-31, accession 0001178670-25-000090. Derived: 6-month figure less the 3-month figure.Report this figure43.7Operating cash flow, Q3 FY2024, three months to 2024-09-30$43.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001628280-25-047345. Derived: 9-month figure less the 6-month figure.Report this figure(94.7)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$94.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure(118)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$118.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure128Operating cash flow, Q2 FY2025, three months to 2025-06-30$127.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001178670-26-000062. Derived: 6-month figure less the 3-month figure.Report this figure297Operating cash flow, Q3 FY2025, three months to 2025-09-30$296.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001178670-26-000076. Derived: 9-month figure less the 6-month figure.Report this figure218Operating cash flow, Q4 FY2025, three months to 2025-12-31$217.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure341Operating cash flow, Q3 FY2026, three months to 2026-09-30$341.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001178670-26-000076. Derived: 9-month figure less the 6-month figure.Report this figure
Capital expenditure$m15.9Capital expenditure, Q2 FY2023, three months to 2023-06-30$15.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-08-01, accession 0001178670-24-000041. Derived: 6-month figure less the 3-month figure.Report this figure17.1Capital expenditure, Q3 FY2023, three months to 2023-09-30$17.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-10-31, accession 0001178670-24-000053. Derived: 9-month figure less the 6-month figure.Report this figure15.3Capital expenditure, Q4 FY2023, three months to 2023-12-31$15.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure13.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$13.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure8.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$8.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-07-31, accession 0001178670-25-000090. Derived: 6-month figure less the 3-month figure.Report this figure4.2Capital expenditure, Q3 FY2024, three months to 2024-09-30$4.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0001628280-25-047345. Derived: 9-month figure less the 6-month figure.Report this figure9.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$9.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure9.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$9.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure14.3Capital expenditure, Q2 FY2025, three months to 2025-06-30$14.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001178670-26-000062. Derived: 6-month figure less the 3-month figure.Report this figure12.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$12.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001178670-26-000076. Derived: 9-month figure less the 6-month figure.Report this figure23.3Capital expenditure, Q4 FY2025, three months to 2025-12-31$23.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001628280-26-007497. Derived: 12-month figure less the 9-month figure.Report this figure69.8Capital expenditure, Q3 FY2026, three months to 2026-09-30$69.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001178670-26-000076. Derived: 9-month figure less the 6-month figure.Report this figure

Shares

Diluted shares (weighted)138.04m, Q3 FY2026
Alnylam Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q2 FY20262026-06-30Q3 FY20262026-09-30
Diluted shares (weighted)m shares122Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30122,166,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0001178670-23-000023.Report this figure124Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31124,111,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-02, accession 0001178670-24-000023.Report this figure125Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30124,659,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-01, accession 0001178670-24-000041.Report this figure131Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30131,337,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-10-31, accession 0001178670-24-000053.Report this figure126Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31126,138,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure127Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30126,733,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-07-31, accession 0001178670-25-000090.Report this figure129Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30128,590,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-10-30, accession 0001628280-25-047345.Report this figure130Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31129,676,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-01, accession 0001178670-25-000052.Report this figure131Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30130,628,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure137Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30137,348,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure138Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30138,281,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-30, accession 0001178670-26-000062.Report this figure138Diluted shares (weighted), Q3 FY2026, three months to 2026-09-30138,040,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure

Shares outstanding: 133.94mShares outstanding, period not labelled, at 2026-10-23133,937,576 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-10-29, accession 0001178670-26-000076.Report this figure at Oct 23, 2026, from the cover of the 10-Q filed Oct 29, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 15:25 ET. Listed shows no prices and gives no investment advice.